GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The prevalence of severely obese children is on the rise. Behavioral therapies for weight
loss are successful in some, but others need more aggressive approaches such as drug therapy.
In addition, up to 25% of severely obese children have impaired glucose tolerance (IGT),
which places them at significantly elevated risk of developing type 2 diabetes mellitus and
cardiovascular disease. Although various drug therapies for weight loss and IGT have been
explored in adults, few have been evaluated in children.
Recently, a new drug class has emerged that targets deficiencies of GLP-1. One of the main
glycemic mechanisms of action of the GLP-1 agonists such as exenatide is to enhance glucose
disposal in the postprandial setting and improve glucose tolerance. In addition, exenatide
can induce weight loss by decreasing appetite and slowing gastric motility.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute